Abstract |
We have applied tegaful and uracil (UFT) treatment as adjuvant chemotherapy to patients after the completion of primary therapy. UFT was given per os at a dose of 300 or 400 mg/day for more than 1 year. A retrospective study was conducted on 15 patients, assessed as the UFT-treated group, and 24 patients assessed as the UFT-nontreated group. The 5-year survival rate in patients treated or not treated with UFT was 76.6 and 22.6%, respectively. Among those who underwent surgery in combination with other therapy, the 5-year survival rate was 74.1% with UFT and 27.3% without UFT. In patients receiving chemotherapy plus radiotherapy alone, the 5-year survival rate was 80.0% with UFT and 19.2% without UFT. In 23 patients with proven effects of neoadjuvant chemotherapy comprising 18 PR cases and 5 CR cases, a comparison was made between 10 patients treated with UFT and 13 patients not treated with UFT. As a result, the 5-year survival was 76.2 and 17.9%, respectively. In the patients with T3 disease, who occupied the majority, the 5-year survival rate was 71.4 and 23.8%, respectively. Adjuvant chemotherapy with UFT tends to show a substantial significant difference particularly in patients who were successfully treated with radiotherapy plus chemotherapy as the primary treatment. UFT was clearly shown to have a statistically significant effect, despite a small population. The findings of the present investigation point to the value of conducting further study to ascertain the effect of UFT by a randomized trial in a larger population.
|
Authors | M Fujii, Y Ohno, Y Tokumaru, Y Imanishi, M Kanke, J Kanzaki, Y Inuyama |
Journal | Oncology
(Oncology)
1998 Mar-Apr
Vol. 55
Issue 2
Pg. 109-15
ISSN: 0030-2414 [Print] Switzerland |
PMID | 9499184
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Drug Combinations
- UFT(R) drug
- Tegafur
- Uracil
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, radiotherapy, surgery)
- Chemotherapy, Adjuvant
- Drug Combinations
- Female
- Humans
- Male
- Maxillary Sinus Neoplasms
(drug therapy, radiotherapy, surgery)
- Middle Aged
- Radiotherapy, Adjuvant
- Retrospective Studies
- Survival Analysis
- Tegafur
(administration & dosage, therapeutic use)
- Treatment Outcome
- Uracil
(administration & dosage, therapeutic use)
|